FDA decision calendar · updated Nov 15, 2026

See FDA decisions coming before your brand plan has to react.

Upcoming PDUFA dates and recent approvals, each with a short marketer take on what it means for launch, brand and agency teams. Every row links to its public source.

  • 6 decisions in the next 30 days
  • 19 in the next 90
  • 3 delayed
  • 48 novel approvals in 2026

The Monday email

Next 90 days

PDUFA and other FDA decision dates from Nov 15, 2026 to Feb 13, 2027.

Nov222026
DelayedPDUFA datein 7 days

Molbreevi (molgramostim)

Savara (SVRA) · Pulmonology, Rare disease

Autoimmune pulmonary alveolar proteinosis (aPAP)

Marketer take: Rare pulmonary launch; the review was already extended three months, so plan launch materials with date-slip contingency.

Source: SEC filing · Last verified Nov 15, 2026

Nov222026
DelayedPDUFA datein 7 days

Deramiocel

Capricor Therapeutics (CAPR) · Neurology, Rare disease

Duchenne muscular dystrophy (DMD) cardiomyopathy

Marketer take: The FDA advisory committee voted against effectiveness in July 2026 and the date was extended, so DMD teams should treat the outcome as uncertain.

Source: SEC filing · Last verified Nov 15, 2026

Nov272026
UpcomingPDUFA datein 12 days

BBP-418

BridgeBio Pharma (BBIO) · Neurology, Rare disease

Limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9)

Marketer take: Potential first therapy in a very small neuromuscular population, where patient identification and specialist outreach drive launch.

Source: company press release · Last verified Nov 15, 2026

Nov302026
UpcomingPDUFA datein 15 days

Povetacicept

Vertex Pharmaceuticals (VRTX) · Nephrology

IgA nephropathy (accelerated approval)

Marketer take: Would add another entrant to a fast-growing IgAN market that already includes Trutakna, raising the bar for nephrologist differentiation messaging.

Source: SEC filing · Last verified Nov 15, 2026

Nov302026
UpcomingPDUFA datein 15 days

Bezuclastinib

Cogent Biosciences (COGT) · Oncology

Gastrointestinal stromal tumor (GIST)

Marketer take: The company says it is preparing to launch in GIST, a disease treated by a small group of sarcoma-focused oncologists, so competing GIST brands should expect concentrated, sequencing-focused messaging at the same centers.

Source: company press release · Last verified Nov 15, 2026

Dec122026
UpcomingPDUFA datein 27 days

Quimilza (imsidolimab)

Vanda Pharmaceuticals (VNDA) · Dermatology, Rare disease

Generalized pustular psoriasis (GPP)

Marketer take: Would be a second biologic for generalized pustular psoriasis after Spevigo, so dermatologists will hear differentiation messaging in a rare disease where recognizing GPP flares is still a core education need.

Source: SEC filing · Last verified Nov 15, 2026

Dec172026
UpcomingPDUFA datein 32 days

Relacorilant

Corcept Therapeutics (CORT) · Endocrinology

Cushing's syndrome (resubmitted NDA)

Marketer take: A resubmission decision for the same molecule already approved as Lifyorli in ovarian cancer, so watch for distinct branding and for whether endocrinology messaging on hypercortisolism screening expands with it.

Source: company press release · Last verified Nov 15, 2026

Dec222026
UpcomingPDUFA datein 37 days

Lorundrostat

Mineralys Therapeutics (MLYS) · Cardiovascular

Hypertension, in combination with other antihypertensives

Marketer take: Would compete directly with the recently approved Baxfendy in add-on hypertension, so expect head-to-head positioning in primary care.

Source: SEC filing · Last verified Nov 15, 2026

Dec232026
UpcomingPDUFA datein 38 days

Anito-cel (anitocabtagene autoleucel)

Gilead Sciences (Arcellx) (GILD) · Oncology, Hematology

Relapsed/refractory multiple myeloma, 4th line and later

Marketer take: A new CAR-T entrant in late-line myeloma, where treatment-center onboarding and referral pathways matter more than broad HCP reach.

Source: SEC filing · Last verified Nov 15, 2026

Dec272026
UpcomingPDUFA datein 42 days

Relutrigine

Praxis Precision Medicines (PRAX) · Neurology, Rare disease

SCN2A and SCN8A developmental and epileptic encephalopathies (DEE)

Marketer take: Rare pediatric epilepsy launch where genetic testing and epileptologist outreach drive patient finding.

Source: company press release · Last verified Nov 15, 2026

Dec302026
UpcomingPDUFA datein 45 days

Bezuclastinib

Cogent Biosciences (COGT) · Hematology, Rare disease

Nonadvanced systemic mastocytosis (NonAdvSM)

Marketer take: A second indication decision weeks after GIST, which would let one brand team run two launches with very different audiences.

Source: company press release · Last verified Nov 15, 2026

Jan62027
UpcomingPDUFA datein 52 days

Anktiva (nogapendekin alfa inbakicept) + BCG

ImmunityBio (IBRX) · Oncology, Urology

BCG-unresponsive NMIBC with papillary disease without CIS (sBLA)

Marketer take: A label expansion into papillary-only BCG-unresponsive NMIBC would widen the urologist audience for an existing brand and push competing bladder-sparing therapies to sharpen patient-selection messaging.

Source: company press release · Last verified Nov 15, 2026

Jan212027
UpcomingPDUFA datein 67 days

Zeleciment rostudirsen (DYNE-251)

Dyne Therapeutics (DYN) · Neurology, Rare disease

Duchenne muscular dystrophy (DMD)

Marketer take: Another DMD decision close to Deramiocel's, so DMD brand and advocacy teams face a busy, crowded news cycle.

Source: company press release · Last verified Nov 15, 2026

Jan282027
UpcomingPDUFA datein 74 days

Arikayce (amikacin liposome inhalation suspension)

Insmed (INSM) · Pulmonology, Infectious disease

Expanded label in MAC lung disease (sNDA, priority review)

Marketer take: The company says it would launch under an expanded MAC lung disease label, which would widen the pulmonologist and ID audience beyond the current refractory-patient label.

Source: company press release · Last verified Nov 15, 2026

Jan292027
UpcomingPDUFA datein 75 days

Ulixacaltamide

Praxis Precision Medicines (PRAX) · Neurology

Essential tremor

Marketer take: Essential tremor is a large neurology and primary-care population, so this would be a broad-reach launch compared with most rare-disease decisions.

Source: company press release · Last verified Nov 15, 2026

Feb12027
DelayedPDUFA datein 78 daysMoved from Nov 1, 2026

Mitapivat

Agios Pharmaceuticals (AGIO) · Hematology

Sickle cell disease (accelerated approval sNDA)

Marketer take: Date moved from Nov 1, 2026 while FDA weighs whether a REMS is needed, which could shape how the brand is marketed and dispensed.

Source: SEC filing · Last verified Nov 15, 2026

Feb22027
UpcomingPDUFA datein 79 days

Yeztugo (lenacapavir) 300 mg once-weekly oral

Gilead Sciences (GILD) · Infectious disease

HIV pre-exposure prophylaxis (sNDA)

Marketer take: Would add a weekly oral option to an existing PrEP brand, giving HIV prevention marketers a new dosing-choice message.

Source: SEC filing · Last verified Nov 15, 2026

Feb42027
UpcomingPDUFA datein 81 days

Infigratinib (oral)

BridgeBio Pharma (BBIO) · Endocrinology, Rare disease

Achondroplasia

Marketer take: An oral option in achondroplasia, where Voxzogo and Yuviwel are already approved, so expect route-of-administration messaging.

Source: company press release · Last verified Nov 15, 2026

Further out

Known decision dates beyond 90 days.

Feb232027
UpcomingPDUFA datein 100 days

Zoryve (roflumilast) cream 0.05%

Arcutis Biotherapeutics (ARQT) · Dermatology

Atopic dermatitis in infants down to 3 months (sNDA)

Marketer take: Extending down to infants as young as 3 months would put a nonsteroidal brand in pediatricians' and pediatric dermatologists' offices, where parent-facing steroid-sparing messaging matters.

Source: company press release · Last verified Nov 15, 2026

Feb272027
UpcomingPDUFA datein 104 days

Zipalertinib

Taiho Oncology / Cullinan Therapeutics (CGEM) · Oncology

Relapsed EGFR exon 20 insertion non-small cell lung cancer

Marketer take: Would enter EGFR exon 20 insertion lung cancer, a niche where amivantamab-based regimens are established, so biomarker testing rates and thoracic oncologist reach set the size of the opportunity.

Source: company press release · Last verified Nov 15, 2026

Feb282027
UpcomingPDUFA datein 105 days

Qtorin rapamycin 3.9% anhydrous gel

Palvella Therapeutics (PVLA) · Dermatology, Rare disease

Microcystic lymphatic malformations

Marketer take: The company calls it potentially the first FDA-approved therapy for this condition and is building commercial and medical affairs teams ahead of the date.

Source: company press release · Last verified Nov 15, 2026

Feb282027
UpcomingPDUFA datein 105 days

Oxnimbi (AD109)

Apnimed (APMD) · Sleep, Pulmonology

Obstructive sleep apnea

Marketer take: An oral OSA option would reach sleep specialists and primary care in a market built around CPAP and devices, with tirzepatide already approved for OSA in adults with obesity.

Source: company press release · Last verified Nov 15, 2026

Feb282027
UpcomingPDUFA datein 105 days

Voxzogo (vosoritide)

BioMarin Pharmaceutical (BMRN) · Endocrinology, Rare disease

Achondroplasia in children, full approval (sNDA)

Marketer take: Full approval lands weeks after the oral infigratinib decision, so the incumbent brand will likely lean on its long-term data.

Source: SEC filing · Last verified Nov 15, 2026

Feb282027
UpcomingPDUFA datein 105 days

Amondys 45 (casimersen) and Vyondys 53 (golodirsen)

Sarepta Therapeutics (SRPT) · Neurology, Rare disease

Duchenne muscular dystrophy, sNDAs after confirmatory ESSENCE trial

Marketer take: The confirmatory trial missed its primary endpoint and the company says FDA action could change labels, so DMD marketers should track this closely.

Source: SEC filing · Last verified Nov 15, 2026

Building a launch or tracking a competitor?

Get the next 30 days of FDA decisions in your inbox every Monday, plus alerts when a date moves.

Recent approvals

FDA novel drug approvals (CDER, 2026), newest first.

Nov92026
ApprovedApproved

Sunharbo (asundexian)

Bayer HealthCare Pharmaceuticals · Cardiovascular, Neurology

To reduce the risk of stroke in adults following a recent mild-to-moderate non-cardioembolic ischemic stroke or a high-risk transient ischemic attack

Marketer take: Opens a new drug class in secondary stroke prevention, so neurology and cardiology brand teams should expect new HCP education needs and competitive messaging around antiplatelet regimens.

Source: FDA page · Last verified Nov 15, 2026

Oct202026
ApprovedApproved

Hibsago (bepirovirsen)

GlaxoSmithKline (GSK) · Infectious disease

To treat chronic hepatitis B virus infection in certain adults without cirrhosis, in combination with existing antiviral therapy

Marketer take: An antisense add-on used with existing antiviral therapy in chronic hepatitis B, a market long limited to oral suppressive drugs, so hepatologist and ID education on which patients qualify will be central.

Source: FDA page · Last verified Nov 15, 2026

Oct92026
ApprovedApproved

Hovilpri (pritelivir)

AiCuris Anti-infective Cures · Infectious disease

To treat adults with weakened immune systems who have mucocutaneous lesions caused by herpes simplex virus infection and have not responded to other therapies

Marketer take: A niche launch for refractory HSV in immunocompromised adults, so transplant and oncology-center ID specialists and hospital formulary committees are the core audience.

Source: FDA page · Last verified Nov 15, 2026

Sep282026
ApprovedApproved

Emcitate (tiratricol)

Rare Thyroid Therapeutics · Endocrinology, Rare disease

To treat peripheral thyrotoxicosis in patients with MCT8 deficiency

Marketer take: An ultra-rare pediatric endocrine launch in MCT8 deficiency, where genetic diagnosis, pediatric endocrinology and neurology referrals, and advocacy groups drive patient finding.

Source: FDA page · Last verified Nov 15, 2026

Sep252026
ApprovedApproved

Atebrioz (zilurgisertib)

Mirum Pharmaceuticals (MIRM) · Rare disease

To reduce the volume of total new heterotopic ossification in adults and pediatric patients 12 years and older with fibrodysplasia ossificans progressiva

Marketer take: Enters fibrodysplasia ossificans progressiva alongside Sohonos and Regeneron's Pasatru (approved five weeks earlier), so a tiny specialist community will see three-way differentiation messaging, starting with Atebrioz's label down to age 12.

Source: FDA page · Last verified Nov 15, 2026

Sep252026
ApprovedApproved

Juvmo (tavapadon)

AbbVie (ABBV) · Neurology

To treat Parkinson’s disease in adults

Marketer take: A new Parkinson's option in a crowded, largely generic market built on levodopa and dopamine agonists, so movement-disorder specialists and neurologists will need clear positioning on where it fits in therapy.

Source: FDA page · Last verified Nov 15, 2026

Sep232026
ApprovedApproved

Lyrfigtu (lirafugratinib)

Elevar Therapeutics · Oncology

To adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring a fibroblast growth factor receptor 2 gene fusion or other rearrangement

Marketer take: Limited to previously treated FGFR2 fusion or rearrangement-positive cholangiocarcinoma, so molecular testing rates and reach into GI oncology centers define the market, and existing FGFR inhibitor brands face a direct rival.

Source: FDA page · Last verified Nov 15, 2026

Sep232026
ApprovedApproved

Onswik (insulin efsitora alfa-gobe)

Eli Lilly (LLY) · Diabetes, Metabolic

To improve glycemic control in adults with type 2 diabetes mellitus, as an adjunct to diet and exercise

Marketer take: Lilly's once-weekly basal insulin arrives six months after Novo Nordisk's Awiqli, setting up a direct weekly-insulin positioning fight in endocrinology and primary care where formulary placement decides early share.

Source: FDA page · Last verified Nov 15, 2026

Sep112026
ApprovedApproved

Pixclara (floretyrosine F 18)

Telix Pharmaceuticals (TLX) · Diagnostic imaging, Oncology

To use with positron emission tomography to differentiate recurrent or progressive glioma from treatment-related change in conjunction with other diagnostic evaluations

Marketer take: A PET agent for telling recurrent glioma apart from treatment-related change, so neuro-oncologists, neuroradiologists and nuclear medicine sites are the audience, with tracer availability and reimbursement shaping adoption.

Source: FDA page · Last verified Nov 15, 2026

Sep112026
ApprovedApproved

Isembyld (apitegromab-mstn)

Scholar Rock (SRRK) · Neurology, Rare disease

To treat spinal muscular atrophy in adults and pediatric patients 2 years of age and older who are currently receiving an SMN2-targeted treatment

Marketer take: An add-on for SMA patients already on SMN2-targeted therapy, so it sells alongside existing SMA brands rather than against them; neuromuscular centers and caregiver communities are the key audiences.

Source: FDA page · Last verified Nov 15, 2026

Sep42026
ApprovedApproved

Etcamah (camizestrant)

AstraZeneca (AZN) · Oncology

To treat hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer upon detection of ESR1 mutation during aromatase inhibitor and CDK4/6 inhibitor therapy

Marketer take: Labeled for switching when an ESR1 mutation is detected during aromatase inhibitor plus CDK4/6 therapy, which makes mutation testing during first-line treatment the core message, and it competes with Orserdu and Veppanu in ESR1-mutated disease.

Source: FDA page · Last verified Nov 15, 2026

Sep32026
ApprovedApproved

Zanvastro (zilganersen)

Ionis Pharmaceuticals (IONS) · Neurology, Rare disease

To treat Alexander disease in pediatric and adult patients

Marketer take: Alexander disease had no FDA-approved disease-specific therapy, so this is a category-creating rare neurology launch built on genetic diagnosis, leukodystrophy centers and advocacy groups.

Source: FDA page · Last verified Nov 15, 2026

Aug282026
ApprovedApproved

Mimrylo (rusfertide)

Takeda Pharmaceuticals America (TAK) · Hematology

To treat erythrocytosis in adults with polycythemia vera

Marketer take: A new way to control erythrocytosis in polycythemia vera, so hematologist messaging will center on where it fits relative to phlebotomy and existing cytoreductive drugs.

Source: FDA page · Last verified Nov 15, 2026

Aug272026
ApprovedApproved

Lisraya (brepocitinib)

Priovant Therapeutics · Immunology, Dermatology

To treat dermatomyositis in adults

Marketer take: An oral treatment for dermatomyositis, a condition with few approved options (IVIG is one), so rheumatology and dermatology teams will need education on diagnosis and where an oral therapy fits.

Source: FDA page · Last verified Nov 15, 2026

Aug262026
ApprovedApproved

Rasonque (daraxonrasib)

Revolution Medicines (RVMD) · Oncology

To treat metastatic pancreatic cancer

Marketer take: A targeted option in metastatic pancreatic cancer, one of oncology's hardest-to-treat settings, so expect high oncologist attention and fast pathway reviews at cancer centers and community practices.

Source: FDA page · Last verified Nov 15, 2026

Aug192026
ApprovedApproved

Pasatru (garetosmab-grts)

Regeneron Pharmaceuticals (REGN) · Rare disease

To reduce new heterotopic ossification and clinician-assessed disease flare-ups in adults with fibrodysplasia ossificans progressiva

Marketer take: Joins Sohonos in fibrodysplasia ossificans progressiva and was followed five weeks later by Mirum's Atebrioz, so a very small specialist community will compare three options; Pasatru's label is adults only.

Source: FDA page · Last verified Nov 15, 2026

Aug132026
ApprovedApproved

Zenbexus (iberdomide)

Bristol Myers Squibb (BMY) · Oncology, Hematology

To be used in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent

Marketer take: An oral CELMoD used with daratumumab-based therapy after one prior line including a PI and IMiD, so it targets community oncologists' early-relapse sequencing decisions rather than the late-line centers where CAR-T competes.

Source: FDA page · Last verified Nov 15, 2026

Aug132026
ApprovedApproved

Tauklarify (florquinitau F 18)

Cerveau Technologies (Lantheus) (LNTH) · Diagnostic imaging, Neurology

To be used for positron emission tomography of the brain in adults with cognitive impairment who are being evaluated for Alzheimer disease to identify patients with tau neurofibrillary tangle pathology

Marketer take: A tau PET agent for patients being evaluated for Alzheimer's disease, so memory clinics, neurologists and imaging centers are the audience, and it competes directly with Tauvid.

Source: FDA page · Last verified Nov 15, 2026

Aug52026
ApprovedApproved

Orzeyful (oveporexton)

Takeda Pharmaceuticals USA (TAK) · Neurology, Sleep

To treat narcolepsy type 1

Marketer take: The first orexin agonist for narcolepsy type 1, a new mechanism that sleep specialists will weigh against oxybates and wake-promoting agents, so expect mechanism-of-disease education.

Source: FDA page · Last verified Nov 15, 2026

Jul242026
ApprovedApproved

Simtriyo (centanafadine)

Otsuka Pharmaceutical · Psychiatry

To treat attention-deficit hyperactivity disorder

Marketer take: A new ADHD medicine entering a large, heavily generic market, so psychiatrists, pediatricians and primary care will need clear positioning against stimulants and existing non-stimulants, and payer step edits will be a hurdle.

Source: FDA page · Last verified Nov 15, 2026

Jul242026
ApprovedApproved

Lytenava (bevacizumab-vikg)

Outlook Therapeutics (OTLK) · Ophthalmology

To treat patients with neovascular (wet) age-related macular degeneration

Marketer take: An approved ophthalmic bevacizumab for wet AMD, entering a market where retina specialists already use off-label compounded bevacizumab, so the pitch centers on an FDA-approved, eye-specific formulation and price.

Source: FDA page · Last verified Nov 15, 2026

Jul222026
ApprovedApproved

Jideytro (zidesamtinib)

Nuvalent (NUVL) · Oncology

To treat adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer after receiving a ROS1 kinase inhibitor

Marketer take: For ROS1-positive lung cancer after a prior ROS1 inhibitor, a small biomarker-defined group, so thoracic oncologists and testing labs are the audience and competing ROS1 brands should expect sequencing messages.

Source: FDA page · Last verified Nov 15, 2026

Jul152026
ApprovedApproved

Lipfendra (enlicitide decanoate)

Merck Sharp & Dohme (MRK) · Cardiovascular

To reduce low-density lipoprotein cholesterol

Marketer take: An oral PCSK9 inhibitor that brings the injectable class's mechanism to a pill, which pressures Repatha, Praluent and Leqvio and widens the lipid audience from cardiology into primary care.

Source: FDA page · Last verified Nov 15, 2026

Jul142026
ApprovedApproved

Revtorpyk (gedatolisib)

Celcuity (CELC) · Oncology

In combination with fulvestran, to treat hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting

Marketer take: Labeled for HR+/HER2- breast cancer without a PIK3CA mutation, a different slice of post-endocrine disease than PI3K-pathway drugs aimed at mutated tumors, so biomarker results will steer the oncologist conversation.

Source: FDA page · Last verified Nov 15, 2026

Jul72026
ApprovedApproved

Trutakna (atacicept-vymj)

Vera Therapeutics (VERA) · Nephrology

To reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk for disease progression

Marketer take: Joins a fast-moving IgA nephropathy market (Filspari, Vanrafia, Fabhalta, Tarpeyo) and faces Vertex's povetacicept decision on Nov 30, 2026, so nephrology teams need sharp differentiation.

Source: FDA page · Last verified Nov 15, 2026

Jun262026
ApprovedApproved

Lumvoa (veligrotug-vvze)

Viridian Therapeutics (VRDN) · Ophthalmology, Immunology

To treat thyroid eye disease

Marketer take: A second thyroid eye disease biologic after Tepezza, so ophthalmologists, oculoplastic surgeons and endocrinologists will see head-to-head differentiation messaging.

Source: FDA page · Last verified Nov 15, 2026

Jun172026
ApprovedApproved

Utebzi (tebipenem pivoxil)

GlaxoSmithKline (GSK) · Infectious disease

To treat complicated urinary tract infections, including pyelonephritis, caused by several susceptible microorganisms in adults who have limited or no alternative oral treatment options

Marketer take: The first oral carbapenem in the US, for cUTI patients with limited oral options, which opens a discharge and outpatient message, tempered by antibiotic stewardship controls.

Source: FDA page · Last verified Nov 15, 2026

Jun122026
ApprovedApproved

Ambelvist (gadoquatrane)

Bayer HealthCare · Diagnostic imaging

To detect and visualize lesions with abnormal vascularity, in conjunction with MRI

Marketer take: A gadolinium MRI contrast agent entering a commoditized category, so radiology departments and group purchasing decisions matter more than referring physicians.

Source: FDA page · Last verified Nov 15, 2026

May292026
ApprovedApproved

Cypsedo (cipepofol)

Haisco Pharmaceutical · Anesthesia

To induce general anesthesia in adults undergoing surgery

Marketer take: A new IV general anesthetic, so anesthesiologists, hospital P&T committees and GPO contracts decide uptake against long-entrenched propofol.

Source: FDA page · Last verified Nov 15, 2026

May292026
ApprovedApproved

Xocova (ensitrelvir)

Shionogi · Infectious disease

To use as post-exposure prophylaxis of coronavirus disease 2019 (COVID-19) following contact with an individual who has COVID-19

Marketer take: An oral COVID-19 post-exposure prevention option, unlike treatment-focused Paxlovid, so the audience extends to primary care, urgent care and pharmacies, with seasonal demand.

Source: FDA page · Last verified Nov 15, 2026

May292026
ApprovedApproved

Zaynich (cefepime and zidebactam)

Wockhardt Bio AG · Infectious disease

To treat complicated urinary tract infections, including pyelonephritis, caused by designated susceptible microorganisms

Marketer take: A new IV beta-lactam combination for cUTI, so hospital ID physicians, pharmacists and stewardship committees decide whether it is reserved for resistant organisms.

Source: FDA page · Last verified Nov 15, 2026

May272026
ApprovedApproved

Decnupaz (pivekimab sunirine-pvzy)

AbbVie (ABBV) · Oncology, Hematology

To treat adults with blastic plasmacytoid dendritic cell neoplasm

Marketer take: A CD123-targeted option in BPDCN, an ultra-rare blood cancer where Elzonris was the only approved drug, so the audience is tiny and concentrated in academic hematology centers.

Source: FDA page · Last verified Nov 15, 2026

May222026
ApprovedApproved

Hepcludex (bulevirtide-gmod)

Gilead Sciences (GILD) · Infectious disease, Hepatology

To treat chronic hepatitis delta virus infection in adults without cirrhosis or with compensated cirrhosis

Marketer take: The first US-approved treatment for chronic hepatitis delta, so hepatologists will need help with HDV testing and diagnosis among hepatitis B patients, where it is often missed.

Source: FDA page · Last verified Nov 15, 2026

May152026
ApprovedApproved

Baxfendy (baxdrostat)

AstraZeneca (AZN) · Cardiovascular

To treat hypertension in combination with other antihypertensive drugs

Marketer take: An aldosterone synthase inhibitor for add-on hypertension, a crowded primary-care market where payer access drives uptake, and Mineralys' lorundrostat decision on Dec 22, 2026 sets up a same-class rival.

Source: FDA page · Last verified Nov 15, 2026

May132026
ApprovedApproved

Beqalzi (sonrotoclax)

BeOne Medicines (ONC) · Oncology, Hematology

To treat adults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase inhibitor

Marketer take: A BCL2 inhibitor for mantle cell lymphoma after a BTK inhibitor, a late-line niche where Jaypirca and CAR-T already compete, so lymphoma-focused hematologist-oncologists are the core audience.

Source: FDA page · Last verified Nov 15, 2026

May12026
ApprovedApproved

Veppanu (vepdegestrant)

Rigel Pharmaceuticals (RIGL) · Oncology

To treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy

Marketer take: An oral ER degrader for ESR1-mutated breast cancer after endocrine therapy, competing with Orserdu and AstraZeneca's Etcamah, so ESR1 testing and oncologist sequencing decisions are the battleground.

Source: FDA page · Last verified Nov 15, 2026

Apr202026
ApprovedApproved

Idvynso (doravirine and islatravir)

Merck Sharp & Dohme (MRK) · Infectious disease

To treat HIV-1 infection (as a complete regimen) in adults to replace the current antiretroviral regimen in those who are virologically-suppressed on a stable antiretroviral regimen with no history of virologic treatment failure and no known substitutions associated with resistance to doravirine

Marketer take: A two-drug switch regimen for virologically suppressed adults, competing with Dovato, Biktarvy and long-acting injectables in regimen-simplification conversations with HIV specialists.

Source: FDA page · Last verified Nov 15, 2026

Apr12026
ApprovedApproved

Foundayo (orforglipron)

Eli Lilly (LLY) · Obesity, Metabolic

To reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition, in combination with a reduced-calorie diet and increased physical activity

Marketer take: An oral, non-peptide GLP-1 for weight management that competes on convenience with injectables like Wegovy and Zepbound and pushes obesity care further into primary care.

Source: FDA page · Last verified Nov 15, 2026

Mar262026
ApprovedApproved

Awiqli (insulin icodec-abae)

Novo Nordisk (NVO) · Diabetes, Metabolic

To improve glycemic control in adults with type 2 diabetes mellitus

Marketer take: The first of two once-weekly basal insulins approved in 2026, giving insulin marketers a new dosing-frequency message in primary care; Lilly's weekly Onswik followed in September.

Source: FDA page · Last verified Nov 15, 2026

Mar252026
ApprovedApproved

Lifyorli (relacorilant)

Corcept Therapeutics (CORT) · Oncology

To treat platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer after one to three prior systemic treatment regimens, at least one of which included bevacizumab

Marketer take: A new option in platinum-resistant ovarian cancer after prior bevacizumab, and the same molecule faces a separate Cushing's syndrome decision on Dec 17, 2026, so watch for two brands with very different audiences.

Source: FDA page · Last verified Nov 15, 2026

Mar242026
ApprovedApproved

Avlayah (tividenofusp alfa-eknm)

Denali Therapeutics (DNLI) · Rare disease

To treat certain individuals with Hunter syndrome (Mucopolysaccharidosis type II or MPS II)

Marketer take: Enters Hunter syndrome, where Elaprase has long been the standard enzyme therapy, so metabolic geneticists, lysosomal disease centers and families will look for clear differentiation; it was designed to reach the brain.

Source: FDA page · Last verified Nov 15, 2026

Mar172026
ApprovedApproved

Icotyde (icotrokinra)

Janssen Biotech (Johnson & Johnson) (JNJ) · Immunology, Dermatology

To treat moderate-to-severe plaque psoriasis in patients 12 years and older who weigh at least 40 kg and who are candidates for systemic therapy or phototherapy

Marketer take: An oral IL-23 receptor-blocking peptide for moderate-to-severe psoriasis in patients 12 and older, which challenges injectable IL-23 and IL-17 biologics and Sotyktu on convenience with dermatologists and payers.

Source: FDA page · Last verified Nov 15, 2026

Mar172026
ApprovedApproved

Lynavoy (linerixibat)

Intercept Pharmaceuticals · Hepatology

To treat cholestatic pruritus associated with primary biliary cholangitis

Marketer take: Targets cholestatic itch in primary biliary cholangitis, a symptom-focused niche next to disease-modifying drugs like Iqirvo and Livdelzi, so hepatologists and gastroenterologists will hear quality-of-life messaging.

Source: FDA page · Last verified Nov 15, 2026

Feb272026
ApprovedApproved

Yuviwel (navepegritide)

Ascendis Pharma (ASND) · Endocrinology, Rare disease

To increase linear growth in pediatric patients 2 years and older with achondroplasia with open epiphyses

Marketer take: A once-weekly option in achondroplasia versus daily Voxzogo injections, with oral infigratinib due Feb 4, 2027, so pediatric endocrinologists and families will weigh dosing frequency and route.

Source: FDA page · Last verified Nov 15, 2026

Feb232026
ApprovedApproved

Loargys (pegzilarginase-nbln)

Immedica Pharma · Rare disease, Metabolic

To treat hyperarginemia in adults and pediatric patients two years and older with Arginase 1 Deficiency, in conjunction with dietary protein restriction

Marketer take: An enzyme therapy for Arginase 1 deficiency used alongside protein restriction, so metabolic geneticists and dietitians are the core audience, and newborn screening and specialist centers drive patient finding.

Source: FDA page · Last verified Nov 15, 2026

Feb202026
ApprovedApproved

Bysanti (milsaperidone)

Vanda Pharmaceuticals (VNDA) · Psychiatry

To treat schizophrenia and to treat manic or mixed episodes associated with bipolar I disorder

Marketer take: A new antipsychotic from the maker of Fanapt for schizophrenia and bipolar I mania, entering a crowded, mostly generic market where payer step edits and long-acting injectables shape the psychiatry conversation.

Source: FDA page · Last verified Nov 15, 2026

Feb122026
ApprovedApproved

Adquey (difamilast)

Acrotech Biopharma · Dermatology

To treat mild to moderate atopic dermatitis

Marketer take: A topical PDE4 inhibitor for mild-to-moderate atopic dermatitis, competing with Zoryve, Eucrisa and topical steroids for steroid-sparing positioning with dermatologists and pediatricians.

Source: FDA page · Last verified Nov 15, 2026

Jan122026
ApprovedApproved

Zycubo (copper histidinate)

Sentynl Therapeutics · Rare disease

To treat Menkes disease

Marketer take: The first FDA-approved treatment for Menkes disease, an ultra-rare pediatric copper disorder, so diagnosis in infancy and pediatric neurology and genetics referrals drive the launch.

Source: FDA page · Last verified Nov 15, 2026